Igc pharma announces calma phase 2 trial expansion with the addition of miami jewish health

Potomac, md / access newswire / april 1, 2025 / igc pharma, inc. (nyse american:igc) today announced the expansion of its phase 2 clinical trial, calma, evaluating igc-ad1 for the treatment of agitation in alzheimer's dementia, to mind institute at miami jewish health in miami, florida. this addition further advances the company's efforts to accelerate the trial's completion and builds on promising interim data suggesting the potential of igc-ad1 to improve patient outcomes.
IGC Ratings Summary
IGC Quant Ranking